The latest pancreatic cancer news
ASCO 2022: Nimotuzumab significantly improves overall survival for K-Ras wild-type advanced pancreatic cancer
The addition of nimotuzumab to gemcitabine (Gemzar) increases overall survival in patients with K-Ras wild-type advanced pancreatic…